SCHEMBL10285463

SCHEMBL10285463

Cc1ncccc1-c1nc2c(C)cccc2cc1C(C)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.48
PIK3CD O00329 3/20 0.41
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4D Q08499 1/20 0.37
FABP1 P07148 1/20 0.36
ELANE P08246 1/20 0.36
PDE1A P54750 3/20 0.35
PDE1B Q01064 3/20 0.35
PDE1C Q14123 3/20 0.35
KDM4E B2RXH2 2/20 0.35
GLA P06280 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
VHL P40337 1/20 0.34
PIM1 P11309 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
CCR1 P32246 1/20 0.34
CCR8 P51685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178686 0.89 PIK3CD (0.40) ATMPIK3CDMAPTFABP1L3MBTL1
SCHEMBL1879486 0.84 ATM (0.52) ATMPIK3CDRAB9AMAPTMAPK1
SCHEMBL13853384 0.82 ATM (0.48) ATMPIK3CDRAB9AMAPTMAPK1
SCHEMBL20072420 0.82 PIK3CD (0.34) PIK3CDFABP1PDE1APDE1BPDE1C
SCHEMBL13853391 0.80 PIK3CD (0.47) ATMPIK3CDRAB9AMAPTMAPK1
SCHEMBL28864685 0.76 MET (0.47) ALDH1A1TSHR
SCHEMBL16585129 0.75 PIK3CD (0.53) ATMPIK3CDPIM1PIM2
SCHEMBL4182569 0.75 PIK3CD (0.53) ATMPIK3CDPIM1PIM2
SCHEMBL4191638 0.75 PIK3CD (0.40) ATMPIK3CDMAPTMAPK1ELANE
SCHEMBL15302939 0.74 PIK3CD (0.54) ATMPIK3CDRAB9AMAPTFABP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220585-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-08-30 US disclosed
US-20120220586-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-08-30 US disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220586-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 ATM 750/4885PIK3CD 16/4885RAB9A 2240/4885
US-20120220585-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 ATM 750/4885PIK3CD 16/4885RAB9A 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.